Karolinska Institute

XNK Therapeutics presented two posters at the NK2023 conference in Oslo

Retrieved on: 
Wednesday, September 27, 2023
Abstract, Society, CSO, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, Cell, Patient, Collection, University, Karolinska Institute, Poster, Therapy, Maharashtra University of Health Sciences, Vaccine

HUDDINGE, Sweden, Sept. 27, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.

Key Points: 
  • HUDDINGE, Sweden, Sept. 27, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.
  • XNK Therapeutics participate at NK2023 in Oslo and present the latest research relating to the company's leading natural killer (NK) cell therapies.
  • The poster on BC shows the feasibility of expanding autologous NK cells from peripheral blood mononuclear cells (PBMCs) from BC patients.
  • NK2023 is the 20th annual meeting arranged by the Society of Natural Immunity and takes place in Oslo, Norway, on September 26-29, 2023.

XNK Therapeutics presented two posters at the NK2023 conference in Oslo

Retrieved on: 
Wednesday, September 27, 2023
Abstract, Society, CSO, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, Cell, Patient, Collection, University, Karolinska Institute, Poster, Therapy, Maharashtra University of Health Sciences, Vaccine

HUDDINGE, Sweden., Sept. 27, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.

Key Points: 
  • HUDDINGE, Sweden., Sept. 27, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.
  • XNK Therapeutics participate at NK2023 in Oslo and present the latest research relating to the company's leading natural killer (NK) cell therapies.
  • The poster on BC shows the feasibility of expanding autologous NK cells from peripheral blood mononuclear cells (PBMCs) from BC patients.
  • NK2023 is the 20th annual meeting arranged by the Society of Natural Immunity and takes place in Oslo, Norway, on September 26-29, 2023.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Retrieved on: 
Tuesday, September 12, 2023
Karolinska Institute, Partnership, Therapy, Ramsay, Radiology, Woman, Research, CDR, Guideline, Patient, Reading, Cancer, Hospital, AI, European Society of Radiology, FDA, Breast cancer, Medical imaging

"This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."

Key Points: 
  • "This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."
  • Conducted from April 1, 2021, to June 9, 2022, this study meticulously analyzed 55,581 breast cancer screening cases in real-world clinical settings.
  • Based on the contract, Lunit has integrated Lunit INSIGHT MMG, marking the first-ever actual implementation where AI replaces one of the two human readers in breast cancer screening.
  • "This study signifies a milestone in healthcare, ushering in an era where AI seamlessly complements and elevates the standards of breast cancer screening.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Retrieved on: 
Monday, September 11, 2023
Karolinska Institute, Partnership, Therapy, Ramsay, Radiology, Woman, Research, CDR, Guideline, Patient, Reading, Cancer, Hospital, AI, European Society of Radiology, FDA, Breast cancer, Medical device, Medical imaging

SEOUL, South Korea, Sept. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women.

Key Points: 
  • "This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."
  • Conducted from April 1, 2021, to June 9, 2022, this study meticulously analyzed 55,581 breast cancer screening cases in real-world clinical settings.
  • Based on the contract, Lunit has integrated Lunit INSIGHT MMG, marking the first-ever actual implementation where AI replaces one of the two human readers in breast cancer screening.
  • "This study signifies a milestone in healthcare, ushering in an era where AI seamlessly complements and elevates the standards of breast cancer screening.

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer

Retrieved on: 
Wednesday, September 6, 2023
Human resources, GSK plc, Partnership, Culture, Nephrology, CSL Vifor, Medicine, Doctor of Philosophy, AstraZeneca, Karolinska Institute, Kidney, Growth, Therapy, Kidney disease, Pharmaceutical industry, Management, Puresprings Gospel, Bayer

London— 6 September 2023— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has appointed Fredrik Erlandson as Chief Medical Officer and Peter Mulcahy as Chief People Officer.

Key Points: 
  • London— 6 September 2023— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has appointed Fredrik Erlandson as Chief Medical Officer and Peter Mulcahy as Chief People Officer.
  • Purespring recently appointed Sachin Kelkar as Chief Financial Officer as it confirmed the appointment of Julian Hanak as Chief Executive Officer on a permanent basis.
  • Before joining Purespring, Fredrik served as Head Global Clinical Development at CSL Vifor.
  • Fredrik and Peter both bring unique skills in, respectively, clinical development and talent and organisational design, critical to a Company at our stage of development.

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September

Retrieved on: 
Monday, August 14, 2023
Abstract, Society, CSO, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, University, Karolinska Institute, Therapy, Maharashtra University of Health Sciences

HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies. Two abstracts have been accepted for presentation at the meeting.

Key Points: 
  • XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September
    HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies.
  • Two abstracts have been accepted for presentation at the meeting.
  • NK2023 is the 20th annual meeting arranged by the Society of Natural Immunity and takes place in Oslo, Norway, on September 26-29, 2023.
  • The meeting will attract more than 450 participants and is focused entirely on NK cells, with a preceding day entirely focused on the development of NK cell-based immunotherapies.

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September

Retrieved on: 
Monday, August 14, 2023
Abstract, Society, CSO, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, University, Karolinska Institute, Therapy, Maharashtra University of Health Sciences

HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies. Two abstracts have been accepted for presentation at the meeting.

Key Points: 
  • XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September
    HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies.
  • Two abstracts have been accepted for presentation at the meeting.
  • NK2023 is the 20th annual meeting arranged by the Society of Natural Immunity and takes place in Oslo, Norway, on September 26-29, 2023.
  • The meeting will attract more than 450 participants and is focused entirely on NK cells, with a preceding day entirely focused on the development of NK cell-based immunotherapies.

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November

Retrieved on: 
Monday, August 7, 2023
Abstract, Society, CSO, Cancer, SITC, Immunotherapy, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, Patient, University, Karolinska Institute, Therapy, Environment, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML). Two abstracts have been accepted for presentation at the meeting:

Key Points: 
  • XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.
  • HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML).
  • The yearly SITC meeting is a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.
  • It consists of cutting-edge research presentations by experts in the field.

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November

Retrieved on: 
Monday, August 7, 2023
Abstract, Society, CSO, Cancer, SITC, Immunotherapy, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, Patient, University, Karolinska Institute, Therapy, Environment, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML). Two abstracts have been accepted for presentation at the meeting:

Key Points: 
  • XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.
  • HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML).
  • The yearly SITC meeting is a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.
  • It consists of cutting-edge research presentations by experts in the field.

TATAA Biocenter promotes Sofia Adolfsson to Scientific Officer and Head of Bioinformatics

Retrieved on: 
Tuesday, July 25, 2023
Chief scientific officer, Lund University, Karolinska Institute, TATAA, Head, ETH Zurich, Research, Doctor of Philosophy, Uppsala University, Medicine, Growth, Management, Bioinformatics

GOTHENBURG, Sweden, July 25, 2023 /PRNewswire/ -- TATAA Biocenter AB (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the promotion of Sofia Adolfsson to Head of Bioinformatics and Scientific Officer.

Key Points: 
  • GOTHENBURG, Sweden, July 25, 2023 /PRNewswire/ -- TATAA Biocenter AB (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the promotion of Sofia Adolfsson to Head of Bioinformatics and Scientific Officer.
  • In her new role, Sofia will support the Company's leadership team in its continued growth and long-term ambitions.
  • Sofia previously held roles at the Uppsala University, the Karolinska Institutet, and Lund University before joining TATAA Biocenter in 2021 as Head of Bioinformatics.
  • "Sofia has been an invaluable member of our team since she joined us in 2021," said Mathias Hallin, CEO of TATAA Biocenter.